AUSTIN, Texas, July 20, 2015 /PRNewswire/ -- The Oncology Group today announced that Terry Massey has joined the company as vice president. Mr. Massey will lead The Oncology Group's newest consulting service, revenue recovery.
Mr. Massey has more than 20 years' experience helping oncology programs increase profits and grow operations. In the late 1990s he pioneered Oncology Income Recovery, a contingency-based audit for recovering missed oncology charges due to billing complexities and human error.
During the revenue recovery process, our experts review a practice's past year of charges, identify all that are missed or incorrect, and support them with medical records detail. The practice may then bill anything still within filing deadlines. Medicare claims, for example, may be recovered as far back as 12 months.
"We're all familiar with reasons for incorrect or missed charges — changes in drugs or coding, manual capture or entry methods, employee mistakes, turnover, or understaffing, to name a few," said Steve Black, president of The Oncology Group. "Terry and our experts conduct a thorough charge capture review of medical oncology charges, and finds revenue that would have otherwise been lost. He has an impressive track record of enhancing practices' profits, and we're looking forward to him bringing great results to The Oncology Group clients."
Mr. Massey's career includes controller and CFO roles at major, publicly traded physician practice management firms as well as privately owned oncology practices. A CPA, Terry earned his MBA in finance from the University of North Texas and his bachelor degree in accounting from Harding University.
Specializing in both the clinical and administrative aspects of oncology, The Oncology Group has consulted with more than 300 hospitals and cancer programs across 38 states to build, develop and expand their cancer programs, facilities and operations. For more information, visit http://www.theoncologygroup.com/.
This release was issued through Send2Press(R), a unit of Neotrope(R). For more information, visit Send2Press Newswire at https://www.Send2Press.com
SOURCE The Oncology Group